Patient Derived Xenograft (PDX) models are living biological systems that help researchers understand cancer progression and test potential therapies. They involve directly implanting small pieces of fresh tumor tissue from human patients into mice, where the tumor tissue grows in the form of a new tumor (xenograft). This allows researchers to study cancer development in a way that is more clinically relevant compared to conventional models. PDX models play a significant role in accelerating precision oncology research and development. With advances in cancer genomics enabling comprehensive molecular profiling of tumors from cancer patients, there is an increasing demand for PDX models that can better recapitulate complex human tumor biology and heterogeneity to test targeted and immunotherapies.
The global Patient Derived Xenograft Model Market is estimated to be valued at Us$ 60 Mn in 2024 and is expected to exhibit a CAGR Of 4.0% over the forecast period 2024 To 2031, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics
Increasing demand for personalized medicine is one of the major drivers for the growth of the Patient Derived Xenograft Model Market. PDX models are playing a crucial role in advancing precision oncology by enabling ex vivo testing of targeted drugs and immunotherapies based on a patient’s unique tumor molecular profile. They allow researchers to study the efficacy of various treatment options for individual patients, paving the way for personalized treatment regimens. Additionally, increasing R&D investments by pharmaceutical companies in oncology drug development is also fueling the demand for PDX models. PDX models offer a more predictive platform compared to cell lines for preclinical efficacy testing of novel cancer drugs before entering human trials.
SWOT Analysis
Strength: Patient derived xenograft models have several advantages over traditional cell line-based models, as they closely resemble patients' original tumors in biology and genetics. PDX models retain the molecular and cellular heterogeneity of the original patient tumors. Transplanting live tumor tissue directly from a patient into animals also preserves the tumor microenvironment.
Weakness: Establishing PDX models is a technically challenging and time-consuming process. Only around 30-50% of tumors successfully engraft in mice. Xenograft tumor growth can also be slow initially before the models are expanded.
Opportunity: The increasing demand for personalized cancer medicine is driving the PDX model market. These models help researchers test efficacy of potential drugs for specific patient populations. The ability to study patient response in pre-clinical research also enables better clinical trial design and selection of suitable patient cohorts.
Threats: Alternatives such as organoid cultures and tumor-on-a-chip microfluidic devices offer potential for higher engraftment rates and faster tumor growth compared to PDX models. Ethical issues regarding use of animals in research also pose compliance challenges for market growth.
Key Takeaways
The Global Patient Derived Xenograft Model Market Demand is expected to witness high growth over the forecast period of 2024 to 2031. The global Patient Derived Xenograft Model Market is estimated to be valued at US$ 127 million in 2024 and is expected to exhibit a CAGR of 4.0% over the forecast period 2024 to 2031.
North America currently dominates the PDX model market owing to presence of major pharma companies and ongoing investments in cancer research. The region is anticipated to continue its dominance through 2031.Asia Pacific is likely to be the fastest growing market led by increasing R&D spending, growing biotech industry and rising cancer incidence in countries like China and India.
Key players operating in the patient derived xenograft model market are Crown Bioscience Inc., WuXi AppTec, Champions Oncology, Inc., The Jackson Laboratory, ONCODESIGN, CHARTER OAKS LABS, XenoTech. These players are focusing on expanding their model libraries and service offerings to cover more cancer types and subtypes. Strategic collaborations with pharmaceutical companies and academic institutions are also being pursed for market expansion
Get more insights on this topic :
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian